中國恆大(03333.HK)重申經營正常 累計銷售回款4,521億人民幣
中國恆大(03333.HK)公布,目前,公司經營正常健康、財務穩健。本月24日止,累計實現銷售5,049億人民幣(下同),按年增長11.4%;銷售回款4,521億元,增長51.3%。6月止,現金餘額2,046億元。
本月起,公司推出全國樓盤大優惠,計劃在9月、10月兩個月累計實現2,000億元銷售;全國在建項目共866個,均在正常開工建設。
本月24日止,公司有息負債較3月底下降約534億元,融資成本下降2.24個百分點;提前歸還本月25日後到期借款435億元,各項降負債成效顯著。
公司成立24年來,共計借款20,523筆,從未出現利息晚付、本金逾期歸還的情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.